Brazil patent protection ' could this be the end of Pfizer's Viagra there?; Korea rules a against Lipitor patent

29 March 2010

According to Progenericos, the Brazilian Association of the Generic Drug Industry, more than 7 million pills of US drug behemoth Pfizer's Viagra (sildenafil) were sold in Brazil in 2007, representing a market value of around $210 million reals ($116.8 million). It is estimated that, with the end of patent protection of Viagra, its current price will decrease from between 35% and 50%, notes a blogger on the IP Tango web site.

The discussion on whether Viagra will turn into a generic drug this year or in 2011 has probably reached its final stage, and a final court ruling by the Superior Justice Court is expected soon.

The issue may be summarized as follows, says the blogger: did the 20-year patent protection for Viagra in Brazil commence on June 20, 1990, when the patent application was originally filed in the UK (and later abandoned), or did it start only on June 7, 1991, when that application was filed at the European Patent Office?

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical